HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

V Pengo Selected Research

Lupus Coagulation Inhibitor (Lupus Anticoagulant)

7/2015Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles.
5/2015Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk.
8/2013Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile.
6/2013Correct laboratory approach to APS diagnosis and monitoring.
2/2011Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies.
2/2011'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010.
4/2010Antiphospholipid syndrome: critical analysis of the diagnostic path.
3/2010Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome.
2/2010Clinical course of high-risk patients diagnosed with antiphospholipid syndrome.
10/2009Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


V Pengo Research Topics

Disease

33Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome)
04/2019 - 01/2000
16Atrial Fibrillation
01/2024 - 01/2001
16Thrombosis (Thrombus)
04/2019 - 11/2000
13Hemorrhage
01/2024 - 04/2000
7Stroke (Strokes)
01/2024 - 03/2001
7Thromboembolism
07/2015 - 09/2001
4Venous Thromboembolism
10/2012 - 01/2008
3Venous Thrombosis (Deep-Vein Thrombosis)
11/2013 - 03/2010
3Autoimmune Diseases (Autoimmune Disease)
11/2013 - 01/2001
3Embolism (Embolus)
10/2012 - 01/2008
2Renal Insufficiency (Renal Failure)
03/2016 - 06/2013
2Systemic Lupus Erythematosus (Libman-Sacks Disease)
06/2012 - 01/2001
1Ischemic Stroke
01/2024
1Body Weight (Weight, Body)
12/2017
1Thrombocytopenia (Thrombopenia)
12/2017
1Vascular Diseases (Vascular Disease)
11/2016
1Frailty
11/2016
1Rubella (German Measles)
11/2013
1Hyperferritinemia
11/2013
1Hemorrhagic Stroke
10/2012
1Atherosclerosis
10/2012
1Hypertension (High Blood Pressure)
10/2012
1Heart Failure
10/2012
1Heart Block
05/2012
1Congenital heart block
05/2012
1Birth Weight (Birth Weights)
03/2010
1Infections
03/2010
1Disease Progression
02/2010
1Hypoxia (Hypoxemia)
06/2009
1Right Ventricular Dysfunction
06/2009
1Cardiovascular Diseases (Cardiovascular Disease)
01/2009
1Dementia (Dementias)
11/2004
1Necrosis
09/2002
1Ketosis
09/2002
1Diabetic Ketoacidosis (Ketoacidosis, Diabetic)
09/2002
1Neoplasms (Cancer)
11/2000

Drug/Important Bio-Agent (IBA)

19AntibodiesIBA
10/2018 - 01/2001
17AnticoagulantsIBA
01/2024 - 11/2000
12Antiphospholipid AntibodiesIBA
04/2019 - 01/2001
11Lupus Coagulation Inhibitor (Lupus Anticoagulant)IBA
07/2015 - 01/2008
10Immunoglobulin G (IgG)IBA
07/2015 - 01/2000
6Vitamin KFDA Link
10/2018 - 01/2008
6Warfarin (Coumadin)FDA LinkGeneric
11/2016 - 04/2000
5Glycoproteins (Glycoprotein)IBA
12/2017 - 01/2001
5Immunoglobulin M (IgM)IBA
11/2013 - 04/2010
4Proteins (Proteins, Gene)FDA Link
12/2017 - 01/2001
4Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
10/2012 - 09/2001
3SuspensionsIBA
11/2016 - 04/2000
3DabigatranFDA Link
11/2016 - 11/2011
3RivaroxabanIBA
11/2016 - 10/2012
3AutoantibodiesIBA
06/2013 - 01/2000
3beta 2-Glycoprotein I (Apolipoprotein H)IBA
06/2012 - 01/2008
3Anticardiolipin AntibodiesIBA
02/2011 - 01/2001
3fibrin fragment D (D-dimer)IBA
09/2010 - 06/2009
3Cardiolipins (Cardiolipin)IBA
02/2010 - 01/2001
2apixabanIBA
11/2016 - 10/2012
2Heparin (Liquaemin)FDA LinkGeneric
06/2012 - 06/2012
1Cytochrome P-450 CYP2C9IBA
12/2017
1low density lipoprotein receptor-related protein 8IBA
12/2017
1Platelet Factor 4IBA
12/2017
1Thromboxane B2IBA
12/2017
1Annexin A5IBA
01/2017
1Phospholipids (Phosphatides)FDA LinkGeneric
01/2017
1Ferritins (Ferritin)IBA
11/2013
1Amiodarone (Amiodarona)FDA LinkGeneric
06/2013
1Matrix Metalloproteinase 2 (Gelatinase A)IBA
10/2012
1AntigensIBA
06/2012
1Prothrombin (Factor II)IBA
06/2012
1Fluorinated SteroidsIBA
05/2012
1APTIBA
08/2010
1Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA
06/2009
1Brain Natriuretic Peptide (Natrecor)FDA Link
06/2009
1Troponin IIBA
06/2009
1Estrogens (Estrogen)FDA Link
01/2009
1AntioxidantsIBA
01/2009
1VitaminsIBA
01/2009
1idraparinuxIBA
01/2008
1oxidized low density lipoproteinIBA
01/2008
1Nadroparin (Nadroparin Calcium)IBA
01/2005
1Peptides (Polypeptides)IBA
09/2003
1ThrombomodulinIBA
09/2002
1Messenger RNA (mRNA)IBA
09/2002
1CytokinesIBA
09/2002
1NitratesIBA
09/2002
1Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA
09/2002
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
09/2002
1Nitric Oxide (Nitrogen Monoxide)FDA Link
09/2002
1Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA
09/2001
1Carrier Proteins (Binding Protein)IBA
01/2001
1Complement Factor H (Factor H)IBA
01/2001
1Complement C4 (Complement Component 4)IBA
01/2001
1Kallikreins (Kallikrein)IBA
01/2001
1FibrinIBA
01/2000

Therapy/Procedure

12Therapeutics
01/2024 - 11/2000
2Secondary Prevention
06/2012 - 06/2012
1Stents
02/2013
1Percutaneous Coronary Intervention
02/2013
1Cardiopulmonary Resuscitation (CPR)
03/2010
1Plasma Exchange
08/2008